Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

Todd Neale

June 06, 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Daily News

Defying Earlier GLP-1 Data, Study in Teens Sees Possible Mental Health Gains

L.A. McKeown

October 22, 2024

News Daily News

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Michael O'Riordan

August 21, 2024

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

Todd Neale

April 12, 2024

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Todd Neale

January 12, 2024

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Skin Cancer Risk With Common Diuretics Confirmed Anew

L.A. McKeown

April 14, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

Defying Earlier GLP-1 Data, Study in Teens Sees Possible Mental Health Gains

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Skin Cancer Risk With Common Diuretics Confirmed Anew

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content